All In Biotech

Drug Trial Radar · NCT06530810

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

A Phase 1b, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10382 Combination Therapy in Patients With Chronic Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

May 8, 2026

Study completion May 8, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. Flumatinib is the first approved second generation TKI in China and a derivative of imatinib. The primary objective of this study is to evaluation the safety and tolerability and of HS-10382 combination therapy in patients with chronic myeloid leukemia (CML). The secondary objectives is to evaluate the PK profile, major metabolites and efficacy of HS-10382 in CML-CP/AP subjects after combination therapy, and to explore the kinase domain mutations associated with TKI resistance

Conditions

  • Chronic Myelogenous Leukemia
  • CML Chronic Phase
  • CML Accelerated Phase

Interventions

  • HS-10382+FlumatinibDrug

    Drug:HS-10382+Flumatinib HS-10382 is administered orally BID Drug:Flumatinib Flumatinib 400mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) for HS-10382 combined treatmentTime frame: Up to day 28 from the first dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.